Roivant Sciences revenue and financials
$35.53Change from previous close: −0.70%Absolute change: −$0.25
In the fiscal year ended March 2026, Roivant Sciences reported revenue of $8.26M (−71.57% year over year). The net loss was $299.77M.
Fiscal year ending in March. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- −71.57%
- FY to Mar 2026 vs FY to Mar 2025
- Net margin
- -3,629.2%
- FY to Mar 2025: -592.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | FY to Mar 2026 | FY to Mar 2025 | FY to Mar 2024 | FY to Mar 2023 | FY to Mar 2022 | FY to Mar 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -750 | -839 | -765 | -843 | -678 | -552 |
| Depreciation and amortization | 3.3 | 14.1 | 22.0 | 18.9 | 5.9 | — |
| Capital expenditure | -8.2 | -4.6 | -1.4 | -12.7 | -17.4 | -5.8 |
| Investing cash flow | -682 | -1,766 | 5,204 | -44.3 | 303 | — |
| Financing cash flow | 134 | -1,220 | 419 | 499 | 307 | — |
| Share repurchases | -367 | -1,293 | 0.0 | 0.0 | — | — |
| Debt issued | — | 0.0 | 0.0 | 160 | 36.4 | — |
| Debt repaid | 0.0 | -52.8 | -30.7 | -30.1 | — | — |
| Effect of exchange rates | 3.8 | 0.7 | 0.6 | 6.3 | — | — |
| Net change in cash | -1,295 | -3,825 | 4,858 | -382 | -67.6 | — |
| Free cash flow | -759 | -844 | -767 | -856 | -695 | — |
| Levered free cash flow | -1,090 | -375 | -344 | -410 | 36.9 | — |